ERBB2 and breast neoplasm: In fact, we are trying to overcome one of the limitations of our study, which is based on the results generated in a single CAF line: we currently have more than 10 fibroblast lines obtained from HER2-positive breast tumour samples and several BCCLs with HER2-positive phenotype, where we intend to confirm the preclinical utility of the results presented here.